Right patient, right treatment, right time: biosignatures and precision medicine in depression.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Data-driven biological subtypes of depression: systematic review of biological approaches to depression subtyping.Molecular psychiatry · 2019
   Pooled it
2. Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial.Journal of affective disorders · 2018
   Trial
3. Platelet-Derived Growth Factor as an Antidepressant Treatment Selection Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI Combination.The international journal of neuropsychopharmacology · 2017
   Trial
4. Evaluation ofJournal of cardiovascular development and disease · 2026
   Article
5. Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program.Schizophrenia (Heidelberg, Germany) · 2025
   Article
6. Current progress in targeted pharmacotherapy to treat symptoms of major depressive disorder: moving from broad-spectrum treatments to precision psychiatry.CNS spectrums · 2025
   Review
7. Estimating optimal decision trees for treatment assignment: The case of K > 2 treatment alternatives.Behavior research methods · 2024
   Article
8. The gut-brain axis in depression: Are multi-omics showing the way?Cell reports. Medicine · 2024
   Article
9. Biomarker-Guided Tailored Therapy in Major Depression.Advances in experimental medicine and biology · 2024
   Review
10. Views on sharing mental health data for research purposes: qualitative analysis of interviews with people with mental illness.BMC medical ethics · 2023
    Article
11. Key considerations in the pharmacological management of treatment-resistant depression.Expert opinion on pharmacotherapy · 2021
    Article
12. Can (immune and other) gene expression help us to treat depression?Brain, behavior, & immunity - health · 2021
    Article
13. Gene expression studies in Depression development and treatment: an overview of the underlying molecular mechanisms and biological processes to identify biomarkers.Translational psychiatry · 2021
    Review
14. Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation.International journal of molecular sciences · 2018
    Review
15. Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools.BMC psychiatry · 2017
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.